A significant number of gene therapies are expected to come to market imminently, potentially revolutionizing health care systems. Developers will face significant clinical, regulatory and logistical challenges in bringing these therapies to market. Manufacturers and payers must work through the associated administrative, logistical and legal challenges in partnership.